For Research Use Only – Not for Human Consumption. For Research Use Only. Not for Human Consumption. Not for diagnostic, therapeutic or medical use. Statements have not been evaluated by the FDA.
Tesamorelin and Ipamorelin: One Approved Ingredient, One Not, No Blend Data
Tap to zoom
Key points
- A named pairing of tesamorelin (stabilized GHRH analog) and ipamorelin (ghrelin-receptor agonist).
- Tesamorelin alone has one narrow FDA-approved use (Egrifta, HIV lipodystrophy); ipamorelin is not approved.
- No blend trials and no claims that the combination is better than either part.
What it is
This card names tesamorelin and ipamorelin as separate constituents. They are from different classes, a GHRH analog and a ghrelin-receptor agonist.
How researchers study it
Both are used in studies of the pituitary growth-hormone axis. The card compares the two sets of research themes without suggesting that they should be used together.
What the evidence shows
Tesamorelin has moderate evidence tied to one narrow approved indication, and ipamorelin has limited human data. No trial has tested the pairing, so superiority claims have no support.
Regulatory status
The blend is not FDA-approved. Tesamorelin on its own is approved as Egrifta for HIV-associated lipodystrophy only, ipamorelin is not approved, and WADA prohibits both. This research-use-only material is not prescribing information.
